Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REP-002
- Development stage
- Unknown
- Lead developer
- Model Medicines
- Modality
- Small Molecules
01
Overview
REP-002 is a small-molecule drug candidate reported by Repurpose.AI, later known as Model Medicines, as one of its internally discovered pipeline assets for neurological disorders. Publicly accessible information identifies it only at a high level as a patent-pending, Phase II/III-ready candidate discovered using the company's AI-enabled drug discovery and repurposing platform, but does not clearly disclose the underlying active ingredient, molecular target, mechanism of action, formulation, or precise indication. Because the identity and pharmacology of the asset are not publicly resolved in the available sources, REP-002 is best described as an investigational neurological-disorder program with limited disclosed technical detail.
Beyond the preview
Go deeper on REP-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REP-002.